Zymeworks rises as ovarian cancer drug gets FDA fast-track status

Zymeworks

30/03/2026 11:09

** Shares of biotech firm Zymeworks ZYME.O rise 3% to $24.90 premarket

** Co says U.S. FDA has granted Fast Track status to its experimental drug ZW191 for advanced ovarian cancer, a disease where tumors no longer respond to standard platinum-based chemotherapy

** Adds drug is being tested in an early-stage study to assess safety and early signs of benefit in patients with advanced solid tumors

** ZW191 is an experimental antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells carrying folate receptor‑alpha, commonly found in aggressive ovarian tumors - ZYME

** Co says FDA decision applies regardless of patients’ protein levels, which could allow broader use if approved

** Fast Track is meant to speed development and regulatory review for drugs targeting serious conditions with limited treatment options

** Shares rose ~80% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))